Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback